Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: VISICOL

« Back to Dashboard
Visicol is a drug marketed by Salix Pharms and is included in one NDA. It is available from one supplier.

The generic ingredient in VISICOL is sodium phosphate, dibasic anhydrous; sodium phosphate, monobasic, monohydrate. There are one thousand three hundred and nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sodium phosphate, dibasic anhydrous; sodium phosphate, monobasic, monohydrate profile page.

Summary for Tradename: VISICOL

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list2

Clinical Trials for: VISICOL

A Comparison of the Efficacy and Safety of HalfLytely Vs Visicol Prior To Colonoscopy.
Status: Completed Condition: Colonoscopy

Patient Preference With Visicol Tablet Preparation for Colonoscopy
Status: Completed Condition: Preparation for Colonoscopy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms
VISICOL
sodium phosphate, dibasic anhydrous; sodium phosphate, monobasic, monohydrate
TABLET;ORAL021097-001Sep 21, 2000DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VISICOL

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Salix Pharms
VISICOL
sodium phosphate, dibasic anhydrous; sodium phosphate, monobasic, monohydrate
TABLET;ORAL021097-001Sep 21, 20005,616,346<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc